{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009840","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.165923+00:00","generated_at":"2026-05-16T10:50:14.390737+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY","bullets":["Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).","MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.","clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).","Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.","Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009840","json":"https://secwatch.observer/filing/0001193125-26-009840.json","markdown":"https://secwatch.observer/filing/0001193125-26-009840.md","text":"https://secwatch.observer/filing/0001193125-26-009840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/0001193125-26-009840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/d29941d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:14.390737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}